Articles - Page 24 of 69 - Drugs in Context

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study

Giuseppe Cicero MD PhD, Raffaele Addeo MD, Rossella De Luca PhD, Giuseppe Lo Re MD PhD, Leonardo Gulotta MD, Pierenrico Marchesa MD, Gaspare Gulotta MD PhD

Article Type

Original Research

Published

18 Sep 2020

This study evaluates the safety and
efficacy of TAS-102 in heavily pretreated elderly patients with
metastatic colorectal cancer.

Bempedoic acid for the treatment of dyslipidemia

Joel C Marrs PharmD, MPH, Sarah L Anderson PharmD

Article Type

Review

Published

24 Aug 2020

This narrative review aims to present and discuss the current evidence regarding the use of bempedoic acid for low-density lipoprotein-cholesterol lowering in patients with dyslipidemia and its potential role as an agent to lower cardiovascular events.

Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance

Adam Kisling MD, Jason Jones MD, Caleb Hixson DO FCAP, David Hostler MD MPH FACP, Jordanna Hostler MD FACP

Article Type

Case Report

Published

18 Aug 2020

This article presents a case of ICEP in which mepolizumab was used as a steroid-sparing agent, resulting in improvement in markers of disease activity
and corticosteroid requirement.

Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United States

Arpita Nag PhD, Rebecca Bornheimer BA, Gerry Oster PhD

Article Type

Original Research

Published

12 Aug 2020

The objective of this retrospective cohort study was to examine patterns of use of linaclotide and lubiprostone, primarily focusing on duration of treatment and switching between agents, in patients with CIC, with and without IBS, using a large US health insurance claims database.

Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study

Hae-Jin Suh Oh MD, Ángeles Flórez Menéndez PhD, Víctor Sacristán Santos MD, Francisca Fernández Ribeiro PharmD, Lucía Vilanova-Trillo DNP, Manuel Constenla Figueiras PhD, Manuel Pereiro Ferreiros PhD

Article Type

Original Research

Published

05 Aug 2020

This study evaluates the impact of cutaneous adverse events on quality of life in outpatients receiving anticancer drugs and aims to determine the differences in quality of life between conventional chemotherapy versus targeted therapies.